Chronic myeloid leukemia treatment with recombinant α2-interferon

I. Strozha, V. Petukhov, D. Bondare, G. Feldmane, A. Duks, I. Teilane, I. Medne, M. Mauritsas, L. Grinberga

Research output: Contribution to journalArticlepeer-review

Abstract

A trial has been conducted of recombinant α2-interferon (reaferon) used in 32 patients with Ph'-positive chronic myeloid leukemia (CML). A chronic stage was in 3, transient in 3 and blast in 1 patients. 25 CML patients were newly diagnosed. The treatment lasted from 2 months to 3 years. Clinicohematological remission was confirmed conventionally and by the degree of Ph'-positive clone reduction. An attempt is made to clarify the mechanism underlying the resistance to reaferon basing on the immunological data (detection of antireaferon neutralizing antibodies). The authors propose a combined treatment (myelosan plus reaferon) of CML which has obvious advantages over myelosan monotherapy.

Original languageEnglish
Pages (from-to)62-66
Number of pages5
JournalTerapevticheskii Arkhiv
Volume65
Issue number10
Publication statusPublished - 1993
Externally publishedYes

Field of Science

  • 3.2 Clinical medicine

Publication Type

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint

Dive into the research topics of 'Chronic myeloid leukemia treatment with recombinant α<sub>2</sub>-interferon'. Together they form a unique fingerprint.

Cite this